Back to discover
Disease

Cancer Pain

Late-stage therapeutic developmentEmerging researchRising momentum
MeSHCancer Pain
3
Publications
24
Clinical trials
1
Related conditions
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 6 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones16View all 16
Results expected 5
Recently completed 5
Other updates 4
+8 more in the activity timeline below
Activity timeline16

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Fentanylapproved

Approval — PecFent is indicated for the management of breakthrough pain in adults who are already re… (2010)

Clinical trials

18 sponsors · 7 new · 6 completed in the last 12 months (net +4)

The current development programme across all trial phases.

Clinical programme
24
All trials
6
Active
18
Late-stage
6
Completed
Late-stage studies

Randomized Clinical Trial to Evaluate the Efficacy and Safety of Platelet-Rich Plasma (PRP) Injection Combined With Physical Exercise in Chronic Omalgia

Phase 3 · Recruiting · Biobizkaia Health Research Institute

Does the Perioperative Administration of Dexamethasone Increase the Incidence of Chronic Postmastectomy Pain? A Double-blind Randomized Controlled Trial

Phase 4 · Recruiting · McGill University Health Centre/Research Institute of the McGill University Health Centre

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia

Phase 3 · Recruiting · Axsome Therapeutics, Inc.

A Randomized, Triple-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE)

Phase 3 · Recruiting · Ambros Therapeutics, Inc.

The Efficacy of Ultrasound-guided Bilateral Superficial Cervical Plexus Block on Postoperative Pain Relief in Patients Undergoing Neck Surgeries, Prospective Randomized Controlled Study.

Phase 4 · Active, not recruiting · Sohag University

Fficacy and Safety of Crisugabalin on Nociplastic Pain in Patients With Parkinson's Disease (RELIEF-PD): A Multicentre, Double-Blind, Randomised Controlled Trial

Phase 4 · Active, not recruiting · Guangdong Provincial People's Hospital
Recruiting

Randomized Clinical Trial to Evaluate the Efficacy and Safety of Platelet-Rich Plasma (PRP) Injection Combined With Physical Exercise in Chronic Omalgia

Phase 3 · Recruiting · Biobizkaia Health Research Institute

Does the Perioperative Administration of Dexamethasone Increase the Incidence of Chronic Postmastectomy Pain? A Double-blind Randomized Controlled Trial

Phase 4 · Recruiting · McGill University Health Centre/Research Institute of the McGill University Health Centre

A Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy and Safety of AXS-14 in the Management of Fibromyalgia

Phase 3 · Recruiting · Axsome Therapeutics, Inc.

A Randomized, Triple-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy, Safety, and Tolerability of Intravenous AMBTX-01 (Neridronate) for Treatment of Complex Regional Pain Syndrome Type 1 (CRPS-RISE)

Phase 3 · Recruiting · Ambros Therapeutics, Inc.
Recently completed

Multiprofen-CC™ to Reduce Pain After Total Knee Arthroplasty: A Blinded Randomized Controlled Trial

Phase 3 · Completed · KAZM Pharmaceuticals Inc.

PARASTOP - Paracetamol With Strong Opioids. A Randomized, Double-blind, Parallel-group Non-inferiority Phase III Withdrawal Trial of Paracetamol Versus Placebo in Conjunction With Opioids for Moderate to Severe Cancer-related Pain

Phase 3 · Completed · Oslo University Hospital

Evaluation of the Efficacy of Different Drugs Nebulized at the Glottis on Postoperative Sore Throat in Thyroid Surgery With Nerve Monitoring: a Randomized Controlled Trial

Phase 4 · Completed · Qianfoshan Hospital

Ketamine As Adjuvant to Bupivacaine in Ultrasound Guided Quadratus Lumborum Block for Infants Undergoing Open Pyeloplasty

Phase 4 · Completed · Alexandria University

Ultrasound-Guided Stellate Ganglion Block in Fibromyalgia: A Randomized, Single-Center, Single-Blind, Sham-Controlled Trial

Phase 2/3 · Completed · Sanliurfa Education and Research Hospital

Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery

Phase 3 · Completed · Centre Hospitalier Universitaire, Amiens

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2010emaApproval — Fentanyl· PecFent is indicated for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equi-analgesic dose of another opioid for a week or longer. source ↗
2009emaApproval — Fentanyl· Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.  Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. source ↗
2008emaApproval — Fentanyl· Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20192023
Major themes6
  • Acupressure1
  • Acupuncture Therapy1
  • Cancer Pain1
  • Chronic Pain1
  • Neoplasms1
  • Pain Management1
Leading journals3
  • Current oncology (Toronto, Ont.)1
  • JAMA oncology1
  • Journal of the National Comprehensive Cancer Network : JNCCN1
Leading researchers8
  • Anghelescu DL1
  • Are M1
  • Bruce JY1
  • Buga S1
  • Chwistek M1
  • Cleeland C1
  • Craig D1
  • Gafford E1
Affiliations (unnormalised)6
  • Abramson Cancer Center at the University of Pennsylvania.1
  • Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.1
  • China-Australia International Research Centre for Chinese Medicine1
  • City of Hope National Medical Center.1
  • Cliniques Universitaires Saint Luc1
  • Dana-Farber/Brigham and Women's Cancer Center.1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Neoplasms2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Pain that may be caused by or related to cellular, tissue, and systemic changes that occur during NEOPLASM growth, tissue invasion, and METASTASIS.

Identifiers
MeSHCancer Pain
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.